Antibe Therapeutics’ Founder Leads Study Identifying a Novel Mechanism for Treating Inflammatory Bowel Disease

TORONTO, ONTARIO — (September 5, 2014) — Antibe Therapeutics Inc.’s Founder and Chief Scientific Officer, Dr. John Wallace, is the senior author of an article published this week in the prestigious scientific journal Proceedings of the National Academy of Science USA describing research that may lead to a significant improvement in the treatment of Crohn’s Disease and Ulcerative Colitis, collectively known as “inflammatory bowel disease” (IBD).

IBD affects almost 200,000 Canadians, and many millions of others worldwide. The incidence of IBD is increasing, particularly in young children. There is no cure for IBD, and treatment options are limited and often inadequate.

Dr. Wallace’s research group demonstrated a key role of hydrogen sulfide in promoting repair of intestinal injury. Using mice having a genetic defect similar to that found in many IBD patients, the research demonstrated that small amounts of hydrogen sulfide-releasing agents could rapidly reduce the intestinal inflammation and ulceration that developed in these mice.

Dr. Wallace commented: “We are excited by the results of this study and very grateful to Crohn’s Colitis Canada and the Canadian Institutes of Health Research for funding this research”.

The article can be accessed via the pdf link above.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com

Antibe's subsidiary, Citagenix Inc. ("Citagenix"), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Contact Information
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095
dan.legault@antibethera.com

Please sign up to our mailing list to receive regular news updates via e-mail.